Biotech Values

[mcbio]

I've posted here before on issues with previous P38 programs

It's unclear to me if the "graveyard" reference in your link includes p38 inhibitors that have been tested against pain and, specifically, patients who are no longer responsive to NSAIDs and cannot tolerate opioids. This is the patient population that ARRY is targeting with 797 and it's a very large market and unmet need according to ARRY.